NASDAQ · KOD
Healthcare · Biotechnology
$99.87
Down-$0.61 (-0.61%)
Updated Oct 12, 2026, 8:47 PM
SID Score
6.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · KOD
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
KOD closed at $99.87 after 20 trading sessions, up 201.36% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $94.97 | $100.33 | $93.70 | $99.87 | 1.74M |
| Oct 8, 2026 | $90.01 | $94.95 | $89.54 | $94.26 | 1.53M |
| Oct 7, 2026 | $91.74 | $94.25 | $89.91 | $91.08 | 1.31M |
| Oct 6, 2026 | $92.86 | $95.5439 | $89.70 | $92.34 | 1.48M |
| Oct 5, 2026 | $92.855 | $96.64 | $87.58 | $93.81 | 3.24M |
| Oct 2, 2026 | $98.95 | $98.95 | $88.6303 | $94.45 | 2.68M |
| Oct 1, 2026 | $95.41 | $104.00 | $93.95 | $98.46 | 3.79M |
| Sep 30, 2026 | $93.83 | $98.80 | $88.48 | $94.80 | 4.92M |
| Sep 29, 2026 | $87.20 | $93.1386 | $83.6401 | $91.12 | 6.05M |
| Sep 28, 2026 | $61.705 | $95.77 | $60.49 | $89.92 | 38.55M |
| Sep 25, 2026 | $33.03 | $33.705 | $31.00 | $32.35 | 2.28M |
| Sep 24, 2026 | $30.90 | $33.775 | $29.8101 | $33.22 | 1.29M |
| Sep 23, 2026 | $34.10 | $34.4775 | $30.80 | $31.52 | 1.05M |
| Sep 22, 2026 | $32.71 | $34.45 | $32.46 | $33.80 | 1.04M |
| Sep 21, 2026 | $33.04 | $33.34 | $31.995 | $32.42 | 666.41K |
| Sep 18, 2026 | $32.78 | $32.82 | $31.54 | $32.71 | 1.61M |
| Sep 17, 2026 | $33.32 | $33.69 | $32.725 | $32.85 | 826.15K |
| Sep 16, 2026 | $33.12 | $33.49 | $31.62 | $32.77 | 707.94K |
| Sep 15, 2026 | $32.71 | $33.29 | $32.375 | $32.99 | 819.59K |
| Sep 14, 2026 | $33.21 | $33.89 | $32.96 | $33.14 | 547.79K |
The latest Smart Investors Daily articles mentioning KOD.
Company
Market Activity
Research & News
KOD research
Company profile and research snapshot.
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 28, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 28, 2026 | UBS | Buy | — |
| Sep 28, 2026 | LifeSci Capital | Outperform | — |
| Sep 24, 2026 | Goldman Sachs | Neutral | — |
| Sep 17, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 2, 2026
Kodiak Sciences (NASDAQ:KOD) reported that its Phase III DAYBREAK study met primary endpoints for two investigational treatments in treatment-naïve patients with wet age-related macular degeneration, or wet AMD, with both therapies demonstrating statistical equivalence to aflibercept on visual-acuit
Yahoo · Oct 1, 2026
Kodiak Sciences reported strong endpoint results for its late-stage eye injection candidate, sending its stock soaring.
Yahoo · Sep 30, 2026
Kodiak Sciences tripled in a single session after its eye drug cleared a pivotal trial, but a cash-burning biotech with no revenue and a likely share offering complicates any case for chasing the move.
Yahoo · Sep 29, 2026
Kodiak surges 178% as positive phase III DAYBREAK data show Zenkuda and tabirafusp-ted met key endpoints against Eylea.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning KOD.
